Table 2.
Clinical features of the subjects with TSC (n = 19).
| No | Age/year | Sex | ASD | IQ | Epilepsy type | Onset/months | Epilepsy severity/frequency | Tuber location | mTOR inhibitors | SRS-T score | Vlad MB/SO score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6 | F | Yes | 33 | DEE/FE | 9 | 1 | Multi/RL | No | 102 | 22/38 |
| 2 | 7 | F | Yes | 23 | DEE/FE | 3 | 2/w | Multi/RL | No | 80 | 19/20 |
| 3 | 7 | F | No | 112 | FE | 33 | 1 | Multi/RL | No | 53 | 18/72 |
| 4 | 7 | M | Yes | 25 | DEE | 5 | 1 | Multi/RL | No | 99 | 21/28 |
| 5 | 8 | F | No | 82 | FE | 8 | 1 | Multi/RL | No | 45 | 18/80 |
| 6 | 9 | F | No | 73 | DEE | 5 | 1 | Multi/RL | No | 47 | 17/80 |
| 7 | 9 | M | No | 43 | DEE/FE | 9 | 2/m | Multi/RL | Yes-1 | 76 | 17/45 |
| 8 | 10 | M | No | 96 | NA | 108 | 1 | Multi/L | No | 53 | 15/69 |
| 9 | 10 | M | No | 80 | NA | NA | 0 | Multi/RL | No | 53 | 16/73 |
| 10 | 11 | M | No | 100 | FE | 96 | 1 | Multi/RL | No | 54 | 15/85 |
| 11 | 12 | F | No | 105 | NA | NA | 0 | Multi/L | No | 68 | 19/71 |
| 12 | 13 | F | Yes | 103 | NA | NA | 0 | Multi/RL | No | 83 | 19/88 |
| 13 | 13 | F | Yes | 61 | FE | 65 | 2/m | Multi/RL | Yes-1 | 80 | 20/69 |
| 14 | 14 | F | No | 53 | NA | NA | 0 | Multi/RL | No | 68 | 18/56 |
| 15 | 14 | M | Yes | 45 | FE | 18 | 1 | Multi/RL | No | 86 | 21/37 |
| 16 | 15 | M | No | 88 | FE | 60 | 1 | Multi/RL | No | 61 | 16/77 |
| 17 | 15 | F | No | 105 | NA | NA | 0 | Multi/RL | Yes-2 | 63 | 20/72 |
| 18 | 23 | F | Yes | 49 | FE | 28 | 2/m | Multi/RL | Yes-1 | NA | 20/38 |
| 19 | 28 | F | Yes | 20 | DEE/FE | 6 | 2/w | Multi/RL | Yes-1 | NA | NA/20 |
M, male; F, female; DEE, developmental and epileptic encephalopathies; FE, focal epilepsy; NA, not available; onset/months, epilepsy onset in months; epilepsy severity: 0, never; 1, well controlled (seizure-free for more than a year); 2, refractory epilepsy; w, weekly; m, monthly; multi, multiple cortical tubers; RL, in both hemisphere (right and left); L, in left hemisphere; mTOR inhibitors, yes-1_for refractory epilepsy and yes-2 for subependymal giant cell astrocytoma (SEGA); Vlad MB/SO score, vineland maladaptive behavior score/socialization score.